Skip to main content

Table 1 Burden Assessment Scalea, Aripiprazole Lauroxil Group

From: Aripiprazole lauroxil 2-month formulation with 1-day initiation in patients hospitalized for an acute exacerbation of schizophrenia: exploratory efficacy and patient-reported outcomes in the randomized controlled ALPINE study

  Baseline Week 9 Week 25
All patients (observed cases)
 Total score, patients, n 88 53b 43c
  Mean (SD) 40.8 (14.2) 32.7 (13.1) 31.8 (11.9)
  Change from baseline, mean (SD) −8.4 (10.2) −8.9 (12.4)
Patients who completed 25 weeks of treatmentd
 Total score, patients, n 42 40 42
  Mean (SD) 40.6 (15.1) 33.1 (13.8) 31.7 (12.0)
  Change from baseline, mean (SD) −8.0 (9.8) −8.9 (12.4)
  1. aRange, 19–76
  2. bData from 52 patients contributed to the change from baseline value at week 9
  3. cData from 42 patients contributed to the change from baseline value at week 25
  4. dAll patients who had Burden Assessment Scale data at baseline and week 25